Bergabunglah dengan Buletin Kami
Bergabunglah dengan daftar pelanggan kami untuk mendapatkan artikel terkini, update dan penawaran khusus langsung di kotak masuk Anda
LTG-001 achieved the primary endpoint of the Phase IIb LTG-001-010 trial (NCT071...
Elix and the University of Vienna will partner to bridge the gap between advance...
The collaboration brings together Celonic’s expertise in cell line development, ...
A Phase III trial found the donor-derived cell therapy deramiocel slowed arm mus...
By precisely altering the huntingtin gene rather than switching it off, an in vi...
A GWAS meta-analysis including 2.5 million individuals identified 26 genetic ris...
In a new publishing deal, Causaly and Sage have announced a partnership to bring...
The researchers identified Nys34 as a leading candidate after it demonstrated th...
Manufacturing costs for therapies based on adeno-associated viruses (AAV) could ...
NIBRT predicts that the market for GLP-1 receptor agonist-based diabetes and obe...
Modular flow-through and pseudo-affinity downstream processing technologies enab...
A new perfusion-bioreactor platform developed by researchers in France offers ti...
In a new publishing deal, Causaly and Sage have announced a partnership to bring...
The addition of NanoCellect's technology advances Nova’s strategy of offering a ...
Earlier this month Forte announced positive results for its lead candidate FB102...
By mapping the organization of fascicles and fibers, investigators expect to gai...